• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项回顾性索赔数据库研究,以阐明哮喘患者转诊至专科医生前后的治疗实际情况。

A Retrospective Claims Database Study to Clarify Treatment Reality of Asthma Patients Before and After Referral to a Specialist.

作者信息

Hozawa Soichiro, Ono Keita, Makita Naoyuki, Uchimura Hitomi, Arita Yoshifumi, Hirai Takehiro, Tashiro Naoki

机构信息

Hiroshima Allergy and Respiratory Clinic, Hiroshima, Japan.

AstraZeneca K.K., Tokyo, Japan.

出版信息

J Asthma Allergy. 2024 Jan 18;17:9-19. doi: 10.2147/JAA.S437944. eCollection 2024.

DOI:10.2147/JAA.S437944
PMID:38259253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10802172/
Abstract

PURPOSE

Japanese guidelines recommend that patients with uncontrolled asthma be referred by non-specialists to specialists (allergists and/or pulmonologists). This study investigated the reality of clinical practice in asthma patients referred to specialists in Japan.

PATIENTS AND METHODS

This was a retrospective, observational cohort study of asthma patients in a health insurance claim database (Cross Fact) referred from facilities with non-specialists to those with specialists from January 2016 to December 2018. The referred asthma patients were defined as patients with ≥4 inhaled corticosteroid (ICS)-containing prescriptions during a 1-year baseline period, with an asthma diagnosis, and who had visited a facility with specialists. Asthma exacerbation, maintenance treatment, laboratory tests, and medical procedures before and after referral were analyzed.

RESULTS

Data for 2135 patients were extracted, of which 420 with referral codes were analyzed. The proportion of patients with asthma exacerbations was 50.2% (95% confidence interval [CI]: 45.4-55.1%) before referral and 37.4% (95% CI: 32.7-42.2%) after, a significant decrease (P<0.001; McNemar test). The proportions of patients prescribed ICS alone, long-acting beta-agonists (LABA), and ICS/LABA were lower after referral than before, but the proportions of patients prescribed long-acting muscarinic antagonists (LAMA), ICS/LABA/LAMA, and biologics increased after referral. More asthma-related laboratory tests were performed after referral, and spirometry incidence increased from 16.4% before referral to 51.4% after referral.

CONCLUSION

This study shows a decrease in asthma exacerbations, change in asthma treatments, and increase in laboratory tests after referral to a specialist, suggesting that referrals to specialists lead to better management of asthma.

摘要

目的

日本指南建议,哮喘控制不佳的患者应由非专科医生转诊至专科医生(过敏症专科医生和/或肺病专科医生)处。本研究调查了日本转诊至专科医生处的哮喘患者的临床实际情况。

患者与方法

这是一项回顾性观察队列研究,研究对象为2016年1月至2018年12月期间在医疗保险理赔数据库(Cross Fact)中从非专科医疗机构转诊至专科医疗机构的哮喘患者。被转诊的哮喘患者定义为在1年基线期内有≥4份含吸入性糖皮质激素(ICS)处方、被诊断为哮喘且曾就诊于专科医疗机构的患者。分析了转诊前后的哮喘急性加重情况、维持治疗、实验室检查及医疗程序。

结果

提取了2135例患者的数据,其中420例有转诊编码的患者被纳入分析。转诊前哮喘急性加重患者的比例为50.2%(95%置信区间[CI]:45.4 - 55.1%),转诊后为37.4%(95%CI:32.7 - 42.2%),显著下降(P<0.001;McNemar检验)。转诊后单独使用ICS、长效β受体激动剂(LABA)和ICS/LABA的患者比例低于转诊前,但使用长效毒蕈碱拮抗剂(LAMA)、ICS/LABA/LAMA和生物制剂的患者比例在转诊后有所增加。转诊后进行了更多与哮喘相关的实验室检查,肺功能测定的发生率从转诊前的16.4%增至转诊后的51.4%。

结论

本研究表明,转诊至专科医生后哮喘急性加重情况减少、哮喘治疗发生变化且实验室检查增多,提示转诊至专科医生有助于更好地管理哮喘。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fca/10802172/d4aa622abe7e/JAA-17-9-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fca/10802172/182f907c6ffd/JAA-17-9-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fca/10802172/b7878defd5b1/JAA-17-9-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fca/10802172/d4aa622abe7e/JAA-17-9-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fca/10802172/182f907c6ffd/JAA-17-9-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fca/10802172/b7878defd5b1/JAA-17-9-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fca/10802172/d4aa622abe7e/JAA-17-9-g0003.jpg

相似文献

1
A Retrospective Claims Database Study to Clarify Treatment Reality of Asthma Patients Before and After Referral to a Specialist.一项回顾性索赔数据库研究,以阐明哮喘患者转诊至专科医生前后的治疗实际情况。
J Asthma Allergy. 2024 Jan 18;17:9-19. doi: 10.2147/JAA.S437944. eCollection 2024.
2
Treatment Transitions in Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases.慢性阻塞性肺疾病的治疗转换:对美国和英国医疗数据库的回顾性分析
Pulm Ther. 2022 Mar;8(1):75-93. doi: 10.1007/s41030-021-00180-7. Epub 2022 Jan 10.
3
Adding tiotropium or long-acting β2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization.在吸入性皮质类固醇中添加噻托溴铵或长效β2-激动剂:与哮喘相关的恶化风险和医疗资源利用。
Allergy Asthma Proc. 2023 Nov 13;44(6):413-421. doi: 10.2500/aap.2023.44.230060.
4
Comparative Effectiveness of Long-Acting Beta -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.长效β受体激动剂联合长效毒蕈碱拮抗剂或吸入性糖皮质激素治疗慢性阻塞性肺疾病的比较疗效
Pharmacotherapy. 2017 Apr;37(4):447-455. doi: 10.1002/phar.1913.
5
Inhaled Corticosteroid-Containing Treatment Escalation and Outcomes for Patients with Asthma in a U.S. Health Care Organization.在一个美国医疗机构中,吸入性皮质类固醇治疗升级与哮喘患者的结局。
J Manag Care Spec Pharm. 2017 Nov;23(11):1149-1159. doi: 10.18553/jmcp.2017.23.11.1149.
6
Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.美国哮喘患者中既往医疗保健使用与吸入皮质类固醇和长效β2-肾上腺素能激动剂联合治疗起始的相关性。
Clin Ther. 2009 Nov;31(11):2574-83. doi: 10.1016/j.clinthera.2009.11.007.
7
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma.长效毒蕈碱拮抗剂(LAMA)与吸入性糖皮质激素(ICS)联合使用,对比单独使用相同剂量ICS用于成人哮喘患者的疗效。
Cochrane Database Syst Rev. 2015 Aug 24;2015(8):CD011397. doi: 10.1002/14651858.CD011397.pub2.
8
9
Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan.在起始吸入三联疗法的哮喘患者中的临床特征、治疗模式、疾病负担和持续/依从性:来自日本的真实世界证据。
Curr Med Res Opin. 2020 Jun;36(6):1049-1057. doi: 10.1080/03007995.2020.1763937. Epub 2020 May 14.
10
[The role of fixed dose combinations of inhaled cortikosteroids, long acting beta-2 agonists, and long acting muscarinic antagonists (ICS/LABA/LAMA) in the treatment of asthma].吸入性糖皮质激素、长效β2受体激动剂和长效毒蕈碱拮抗剂固定剂量联合制剂(ICS/LABA/LAMA)在哮喘治疗中的作用
Tuberk Toraks. 2021 Sep;69(3):369-379. doi: 10.5578/tt.20219709.

本文引用的文献

1
Executive summary: Japanese guidelines for adult asthma (JGL) 2021.执行摘要:《2021年日本成人哮喘指南》
Allergol Int. 2023 Apr;72(2):207-226. doi: 10.1016/j.alit.2023.02.006. Epub 2023 Mar 22.
2
The effect of asthma specialist intervention on asthma control among adults.哮喘专科干预对成人哮喘控制的影响。
World Allergy Organ J. 2022 Nov 17;15(11):100712. doi: 10.1016/j.waojou.2022.100712. eCollection 2022 Nov.
3
Diagnosis and Assessment of the Asthmas.哮喘的诊断与评估
J Allergy Clin Immunol Pract. 2023 Jan;11(1):1-8. doi: 10.1016/j.jaip.2022.09.034. Epub 2022 Oct 3.
4
The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study.17 个国家成年人哮喘、花粉热和湿疹负担:GAN 阶段 I 研究。
Eur Respir J. 2022 Sep 15;60(3). doi: 10.1183/13993003.02865-2021. Print 2022 Sep.
5
Real-World Assessment of Asthma Specialist Visits Among U.S. Patients with Severe Asthma.美国重度哮喘患者的哮喘专家就诊的真实世界评估。
J Allergy Clin Immunol Pract. 2021 Oct;9(10):3662-3671.e1. doi: 10.1016/j.jaip.2021.05.003. Epub 2021 Jun 17.
6
Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan.日本严重、未控制的哮喘患者的患病率、疾病负担和治疗现状。
Allergol Int. 2020 Jan;69(1):53-60. doi: 10.1016/j.alit.2019.06.003. Epub 2019 Jul 13.
7
Factors Associated with Physician-Patient Discordance in the Perception of Asthma Control.与哮喘控制感知中医患不一致相关的因素。
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2634-2641. doi: 10.1016/j.jaip.2019.04.046. Epub 2019 May 14.
8
A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan.一项评估日本哮喘患者医疗资源利用情况的回顾性队列研究。
NPJ Prim Care Respir Med. 2019 Apr 29;29(1):13. doi: 10.1038/s41533-019-0128-8.
9
The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA.来自英国和美国的哮喘患者哮喘急性加重的频率及医疗保健利用情况。
BMC Pulm Med. 2017 Apr 27;17(1):74. doi: 10.1186/s12890-017-0409-3.
10
Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma.慢性口服皮质类固醇治疗持续性哮喘成人的负担。
J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1050-1060.e9. doi: 10.1016/j.jaip.2016.12.023. Epub 2017 Feb 10.